Check the plan, the indication, and the state.

Medicare Part D

The Medicare GLP-1 Bridge began July 1, 2026 and runs through December 31, 2027. Eligible adults with Part D drug coverage can pay a $50 copay for a 28- or 30-day fill of certain covered products. The program is nationwide, but coverage is not automatic.

Medicare lists Foundayo tablets, Wegovy injection or tablets, and Zepbound KwikPen only for the Bridge. Its eligibility paths include BMI 35 or higher; BMI 30 or higher with one of several listed conditions; or BMI 27 or higher with specified risk conditions. People whose GLP-1 is already covered by Part D, or who have certain other diagnoses, may follow different Part D rules. A prescriber must submit the prescription and, when requested, prior authorization and lifestyle-program certification. Use Medicare’s eligibility questions for the full criteria.

The $50 is the drug copay under the Bridge. It does not pay for an optional telehealth membership or clinical visit. It does not count toward the Part D deductible or annual out-of-pocket limit and cannot be reduced by Extra Help. CMS explains the payment rules. If you use a separate telehealth service, check its care fee independently.

Medicaid: check your state’s current drug policy

Medicaid coverage for weight management varies by state and can change during the year. A GLP-1 may be handled differently when prescribed for obesity than for another approved indication. A preferred drug list, prior authorization rules and your managed-care plan can also affect a claim. The federal BALANCE model is voluntary for state Medicaid agencies; its existence does not establish your state’s coverage.

These dated primary-source examples show why a national yes/no answer is unreliable:

• California: Medi-Cal Rx says GLP-1 drugs for weight loss are generally excluded beginning January 1, 2026, with a pathway for members under 21 and certain other approved indications. Member notice.
• Massachusetts: MassHealth’s corrected Pharmacy Facts 276 says drugs used only for obesity or overweight are no longer covered from July 3, 2026. It distinguishes other conditions and exceptions. The notice is also listed in MassHealth’s document index.
• North Carolina: NC Medicaid reinstated weight-management GLP-1 coverage effective December 12, 2025, subject to its criteria and preferred drug list.
• Pennsylvania: Its approved state plan amendment, effective January 1, 2026, excludes GLP-1 receptor agonists when used for weight loss.

These are program policies for the stated indication and dates, not a promise about an individual claim. For any state, ask your Medicaid agency or plan for the current formulary, diagnosis rules, prior authorization criteria, preferred product and appeal route.

Employer and Marketplace insurance

HealthCare.gov advises checking your plan’s formulary, Summary of Benefits and Coverage and insurer directly. Ask for the exact drug and form, covered indication, prior authorization or step therapy, in-network pharmacy, deductible and expected copay. If a prescribed drug is denied, ask the plan about an exception or appeal. The Department of Labor explains that private self-funded employer plans are generally outside state health-insurance coverage laws; check your plan document and administrator.

Approval of a prior authorization is not a final price quote. Ask the dispensing pharmacy to run the claim and confirm what you will owe before pickup or shipment. A care membership can be a separate, uncovered charge; for example, Ro says its Body membership is not covered by insurance.

Manufacturer cash-pay offers

Check the drug maker’s own price before adding a telehealth membership. NovoCare lists Wegovy self-pay prices that vary by pill or pen, dose and promotion; its introductory pen offer has a limited number of fills. LillyDirect lists Zepbound self-pay options, and Lilly says its KwikPen price starts at $299 for a specified starting strength. These are conditional product prices, not a uniform annual treatment cost. A commercial-insurance savings card has different rules from a self-pay offer, and either may exclude the clinical-care fee.

HSA or FSA payment is a separate question from insurance reimbursement. IRS Publication 502 treats prescribed drugs as medical expenses and limits weight-loss program expenses to treatment of a physician-diagnosed disease. IRS Publication 969 explains tax-favored account rules. Ask your account administrator whether your exact medication or care fee qualifies; a provider’s “HSA/FSA eligible” label is not a plan-specific determination.

State telehealth and pharmacy rules

HHS says cross-state telehealth practice depends on state rules. A clinician may need a full license, compact privilege or state registration where the patient is located. Ask the service whether its clinician can treat you in your current state and which pharmacy will dispense the prescription.

FDA says compounded GLP-1 drugs are not FDA approved or reviewed for safety, effectiveness and quality before marketing. FDA recommends using a prescription and state-licensed pharmacy, and describes dosing and fraudulent-product concerns. Find your state pharmacy board through FDA. State licensing, drug approval and insurance coverage are separate checks.